Best AASLD Podcasts (2025)

1
Key PBC Studies From AASLD 2025 Podcast 14:58

Play Pause

5d ago14:58

14:58

Listen in as Nancy Reau, MD, reviews key highlights of the most impactful primary biliary cholangitis (PBC) research and gain insights on how to apply these new advances to clinical practice. Topics covered include: Treatment Goals Long-term Data With PPAR Agonists Investigational Therapies for Pruritus Presenter: Nancy Reau, MD Professor of Medici…

1
Bringing Obesity Advances to Primary Care: 2025 in Review and a Look Ahead 25:41

14d ago25:41

25:41

Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including: The Lancet Commission’s new obesity definitions and diagnostic criteria Key data on incretin-based antiobesity medications lik…

1
Setting Our Sights on Symptom Management: Raising the Bar in PBC Management Podcast 38:04

18d ago38:04

38:04

Historically, key symptoms of primary biliary cholangitis (PBC), such as pruritus and fatigue, have been understudied and undertreated. Listen now to learn how symptom management should be considered independently of PBC management, and how new therapeutic agents can help. Topics covered include: Mechanisms of pruritus and fatigue in PBC Nonpharmac…

1
Second-line Agents for Achieving Treatment Goals: Raising the Bar in PBC Management Podcast 16:53

18d ago16:53

16:53

New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now to learn how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals. Topics covered include: Available agents for second-line treatment of PBC An overview of…

1
Defining Our Treatment Goals: Raising the Bar in PBC Management Podcast 17:49

19d ago17:49

17:49

Advancements in our understanding of primary biliary cholangitis (PBC) and new therapeutic agents have reshaped the care landscape of PBC. Listen now to learn how these developments are helping to redefine and elevate treatment goals. Topics covered include: How and when to assess treatment response Risk factors in PBC Biochemical treatment respons…

1
Gaps and Unmet Needs in PBC Care 26:51

1M ago26:51

26:51

Join expert faculty, Dr Alan Bonder and Dr Stuart Gordon, to learn more about key gaps in PBC management and how these shortfalls can be addressed through identification of appropriate biochemical goals, proper assessment and management of PBC symptoms, and current second-line therapies. Presenters: Alan Bonder, MD, AGAF Associate Professor of Medi…

1
Patient Perspectives on New Developments in PBC: Individualizing Patient Care Podcast 12:48

2M ago12:48

12:48

Recent advances in primary biliary cholangitis (PBC) care have resulted in a new focus on personalized care and symptom management. Tune in to learn from patient advocate, Maria G. Morais, RN, how you can integrate patient insights and priorities into treatment plans for PBC. Topics covered include: The Canadian PBC Society Survey: Comorbidities an…

1
Keeping Up With New Developments in PBC 48:04

2M ago48:04

48:04

Tune in to listen as expert faculty, Dr Christopher L. Bowlus and Dr Sonal Kumar, discuss recent developments in treating primary biliary cholangitis (PBC) with new and emerging agents, as well as strategies to integrate these advances into clinical practice. Topics covered include: Methods of Assessing PBC Disease Progression Newer Agents for Seco…

1
S6.14.3 - Louise and Roger React to Empowered SLD Patient Advocates 20:16

3M ago20:16

20:16

By HEP Dynamics LLC

1
S6.14.2 - Goals of the Stephen A. Harrison Patient Advocacy Fellowship Program 19:14

3M ago19:14

19:14

By HEP Dynamics LLC

1
S6.14.1 - How the Harrison Patient Advocacy Fellowship Came To Be 38:22

3M ago38:22

38:22

By HEP Dynamics LLC

1
S6.14 - Introducing the Dr. Stephen A. Harrison Patient Advocacy Fellowship Program 1:07:34

3M ago1:07:34

1:07:34

By HEP Dynamics LLC

1
S6.13.3 - Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism 37:13

4M ago37:13

37:13

Send us a text This discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Roger drives this conversation, focusing on two very different, yet very important is…

1
S6.13.2 - Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease 20:19

4M ago20:19

20:19

Send us a text Last month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, initially developed in 1960, to address modern needs and issues. In this conversation, Professor Krag a…

1
Conversations in Chronic Cough: A Pulmonologist’s Perspective 16:43

4M ago16:43

16:43

Listen as pulmonologist Peter Dicpinigaitis discusses his approach to the diagnosis and management of patients with refractory chronic cough in the context of a clinically relevant case and provides insights regarding emerging therapies. Presenter Peter Dicpinigaitis, MD Professor of Medicine Albert Einstein College of Medicine Division of Critical…

1
S6.13.1 - Major Issues in MASH-ville: Developing a More Integrated Approach to MASH Patient Management 19:48

4M ago19:48

19:48

Send us a text This discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Louise drives this conversation based on two related issues she sees emerging: (i) in…

1
S6.13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health 1:13:53

4M ago1:13:53

1:13:53

Send us a text 00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discuss their recent publication in The Lancet, titled "Screening for Advanced Liver Disease." 00:04:45 -…

1
S6.12.3 - After the Semaglutide Approval: What Next For MASH Therapy? 21:39

4M ago21:39

21:39

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologies and an expanded APP population will play in MASLD and MASH management in the US, and con…

1
S6.12.2 - After the Semaglutide Approval: Expanding MASH Awareness Will Change Medical Practices 22:58

4M ago22:58

22:58

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on how the US healthcare system must adapt to handle the growing number of MASH and MASLD patients who might seek treatment…

1
S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy 24:35

4M ago24:35

24:35

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices. Thi…

1
6.12 - A Second US Drug Approval! What Semaglutide's Success Portends For MASLD Care in the US 1:04:23

4M ago1:04:23

1:04:23

Send us a text 00:00:00 - Surf's Up, Season 6, Episode 12 This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger Green in a discussion that focuses less on specifics of pharmacotherapy and more on how having …

1
6.11.3 - Expert: Emily Andaya Asks Why There Is No "L" In the (Multi-Meatbolic) CKM Initiative 41:03

4M ago41:03

41:03

Send us a text This week's expert interview is with Dr. Emily Andaya, Medical Director of the Cardiovascular Program at Major Health Partners of Shelbyville, IN. She joins Louise Campbell and Roger Green to discuss the American Heart Assocation's CKM initiative, why she believe it should be titled "CKLM" for liver, and how including liver in the CK…

1
6.11.2 - Multi-Metabolic Week Part II: Benefits of the Multi-Metabolic Approach 43:59

4M ago43:59

43:59

Send us a text Multi-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the second of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases. This conversation starts by focusing on how the two…

1
6.11.1 - Multi-Metabolic Week Part I: Role of MASLD In Multi-Metabolic Clinics 37:34

4M ago37:34

37:34

Send us a text Multi-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the first of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases. The core of this episode starts during the weekly gr…

1
6.11 - Multi-Metabolic Practices Integrate MASLD with Other Non-Communicable Diseases 1:49:45

5M ago1:49:45

1:49:45

Send us a text 00:00:00 - Surf's Up: Season 6, Episode 11 This week, we modify our usual episode structure to focus on multi-metabolic practices and constructs. The multi-metabolic practices covered this week are run by non-hepatologists who have chosen to focus on the liver in a broader cardiometabolic context. They include two practices discussed…

1
6.10.3 - Expert: Tim Jobson on Using Basic Data and Analytics to Identify At-Risk Patients 37:16

5M ago37:16

37:16

Send us a text This week's expert is Tim Jobson, Medical Director of Predictive Health Intelligence, a UK-based consultancy. Tim joins Louise Campbell and Roger Green to share an update on PHI's Somerset UK project and other activities. The Somerset pilot was designed to help the NHS identify untreated patients at high risk for liver disease and br…

1
6.10.2 - Newsmakers: LiverRight Launches America's First Virtual Hepatology Clinic 30:49

5M ago30:49

30:49

Send us a text Roger Green talks with LiverRight CEO Brandon Tudor and Chief Medical Officer Alexander Lalos about the launch of LiverRight, America's first virtual hepatology clinic, which has recently begun treating patients. Brandon starts the conversation by telling the story of how he and his partner, Pete Celano, started LiverRight: they saw …

1
6.10.1 - FIrst Six Months, Part I: The Promise of Proteomics For Developing Individualized Treatment Plans 27:36

5M ago27:36

27:36

Send us a text This conversation is the first segment of SurfingMASH’s July discussion of key events from the first six months of 2025. Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green each chose one topic of personal interest. Today, Jörn Schattenberg discusses two recent papers that demonstrate differences in how individual patients re…

1
6.10 - New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening 1:32:25

5M ago1:32:25

1:32:25

Send us a text 00:00 - Surf's Up 6.10.1 This conversation covers three topics. Jörn Schattenberg discusses two papers that suggest an exciting role NITs might play in future prescribing decisions, two executives from LiverRight describe the U.S.'s first virtual liver clinic, and Tom Jobson of Predictive Health Intelligence updates us on how simple …

1
6.9.3 - Expert: Naim Alkhouri Discusses His Long Friendship with Stephen Harrison and His New Role at Summit Clinical Research 29:12

5M ago29:12

29:12

Send us a text Hepatologist and hepatology key opinion leader Naim Alkhouri joins Roger Green to remember his longstanding relationship with Stephen Harrison, announce his new role as Chief Academic Officer at Summit Clinical Research and share how, in this role, he will have exciting new avenues make an impact on many elements of MASH drug develop…

1
6.9.2 - Newsmaker: Fatty Liver Alliance President Mike Betel Discusses His 3rd Annual 30-Day Glucose Challenge 39:31

5M ago39:31

39:31

Send us a text Fatty Liver Alliance President Mike Betel joins Roger Green to discuss his recent completion of the 3rd Annual Glucose Challenge, an event every July where Mike wears a continuous glucose monitor (CGM) device for a month, conducts food experiments, tracks glucose levels and shares all results with his LinkedIn and FattyLiver.ca frien…

1
6.9.1 - #SLDThinkTank2025, Part III: Unique Challenge of Nutrition Management and Role Politicians Can Play 23:35

5M ago23:35

23:35

Send us a text This conversation is the third and final segment of SurfingMASH’s July discussion of #SLDThinkTank 2025. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include Dr. Kristina Curtis of Applied Behaviour Change, a UK-based consultancy. Louise begins this conversation by highlighting the low level o…

1
6.9 - Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and MedEd 1:17:21

5M ago1:17:21

1:17:21

Send us a text 00:00:00 - Surf's Up: Episode 6.9 This conversation covers three topics. The first discusses the challenges of behavior change in dietary habits and ways governments can help, the second looks at what one can learn from wearing a CGM for 30 days, and the third celebrates the late Stephen Harrison while looking into the future of clin…

1
6.8.3 - Deep Dive into Drug Development IV: Other Modes Of Action; Metabolic vs. Pleiotropic Effects 16:59

5M ago16:59

16:59

Send us a text This conversation is the fourth and final segment of SurfingMASH’s April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologist and key opinion leader Sven Francque. The discussion focuses on PPARs, genetic medicines, …

1
6.8.2 - Newsmaker: GLI President and CEO Larry Holden discusses Changes in Washington and How We Can Proceed 31:08

5M ago31:08

31:08

Send us a text Global Liver Institute President and CEO Larry Holden joins Roger Green to discuss recent Washington political and regulatory activities, their potential impact on the liver community, and ways we can respond. Larry starts by acknowledging that we are in for "dark times" under the current administration and describes some current gov…

1
6.8.1 - #SLDThinkTank2025 Part II: Complexities and Challenges of Behavior Change 16:40

5M ago16:40

16:40

Send us a text This conversation is the second segment of SurfingMASH's coverage of the Global Think Tank on Steatotic Liver Diseases (#SLDThinkTank2025) held in Barcelona in June. It focuses on the kinds of feedback most likely to produce successful behavioral interventions. The conversation begins with Jörn discussing the Liver Screen Study, a "v…

1
6.8 - Hybrid Interventions; Washington Challenges; Two-Target Treatment 1:02:58

5M ago1:02:58

1:02:58

Send us a text 00:00 - Surf's Up, Season 6 Episode 8 The conversation addresses three issues that are distinct, yet each is pivotal to the future of MASLD and MASH therapies. The first, from the Global Think-Tank on Steatotic Liver Disease, considers how personal and digital approaches can be combined to form the most effective strategy for patient…

1
S6 - E7.3 - Deep Dive into Drug Development, Part III: NITs in Drug Development 14:55

5M ago14:55

14:55

Send us a text This conversation is the third segment of SurfingMASH’s April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologists and key opinion leaders Sven Francque and Naim Alkhouri. Louise starts the discussion by asking when…

1
S6 - E7.2 - Patient Advocate Jose Willemse on Patient-Centered Care 33:45

5M ago33:45

33:45

Send us a text This week's newsmaker, Dutch Liver Patients Association President Jose Willemse, joins Roger Green to discuss the patient screening program at this year's EASL Congress, which took place in Amsterdam, and the general idea of what constitutes a patient-sensitive dialogue. Jose describes the phenomenal level of interest in the screenin…

1
S6 - E7.1 - #SLDThinkTank2025 Part I: Hybrid Interventions Integrate AI and Human Care 22:33

5M ago22:33

22:33

Send us a text This conversation is the opening segment of SurfingMASH's coverage of the Global Think Tank on Steatotic Liver Diseases (#SLDThinkTank2025) held in Barcelona in June. Co-hosts Louise Campbell and Roger Green are joined by Dr. Kristina Curtis, Managing Director of Applied Behaviour Change, a UK-based consultancy. This discussion start…

1
S6 - E7 - Barcelona SLD Conference Highlight; NITs in Drug Development 1:09:20

5M ago1:09:20

1:09:20

Send us a text 00:00:00 - Surf's Up: Season 6 Episode 7 Host Roger Green explains our recent vacation from publishing episodes, assures the audience that the podcast will continue weekly for months and years ahead, and discusses the episode's sections, covering the Global Think-Tank on Steatotic Liver Disease (SLD), the EASL patient screening activ…

1
Conversations in Chronic Cough: An Otolaryngologist’s Perspective 18:07

6M ago18:07

18:07

Listen as Michael S. Benninger, MD, describes his approach to the diagnosis and management of chronic cough and refractory chronic cough in the context of a clinically relevant case. Presenter Michael S. Benninger, MD Professor of Otolaryngology-Head and Neck Surgery Lerner College of Medicine The Cleveland Clinic President, International Associati…

1
Quality Improvement in Obesity Care: How to Integrate Comprehensive Diabetes Management 19:17

6M ago19:17

19:17

Listen in as Joseph Kim, MD, MPH, MBA, and Colten Bracken, MD, FAAFP, discuss how to integrate comprehensive diabetes management to improve the quality of their obesity care delivery, including: Documenting obesity as a diagnosis for patients with diabetes when appropriate Streamlining processes to ensure patients return for follow-up Dedicating a …

1
Key PBC Studies From EASL and DDW 2025 18:54

6M ago18:54

18:54

In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include: Steatotic liver disease and PBC Vibration-controlled transient elas…

1
Evidence-Based Care in Atopic Dermatitis: Practical Considerations for IL-13 Inhibitors for Moderate to Severe Disease 9:53

6M ago9:53

9:53

In this episode, Daniel C. Butler, MD, and Shawn G. Kwatra, MD, discuss the practical considerations for using IL-13 inhibitors to treat patients with moderate to severe atopic dermatitis, including: Patient candidacy considerations Treatment advancement strategies that go beyond topical therapies The importance of patient-centered care that addres…

1
Evidence-Based Care in Atopic Dermatitis: IL-13 Inhibitors to Treat Moderate to Severe Disease 15:48

6M ago15:48

15:48

In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including: The available biologic therapies that specifically target IL-13 Where these agents fall in the 2024 American Academy of Dermatology treatment algorithm H…

1
Quality Improvement in Obesity Care: How to Manage Prior Authorizations for Antiobesity Medications 27:06

6M ago27:06

27:06

Listen in as Joseph Kim, MD, MPH, MBA; Manish Shah, MD; Martha Grugel, MA, discuss how they manage the prior authorization process for antiobesity agents to improve the quality of their care delivery, including: The information to collect during patient visits The available resources to help you submit prior authorizations The supporting documents …

1
Evidence-Based Care in Atopic Dermatitis: Mapping IL-13 to the Clinical Manifestations of Moderate to Severe Disease 11:40

6M ago11:40

11:40

In this episode, Andrew F. Alexis, MD, MPH, and Daniel C. Butler, MD, discuss the immunopathogenesis and role of IL-13 in atopic dermatitis (AD), including: Contributors to epidermal barrier dysfunction (eg, environmental triggers) IL-13 as a key cytokine in AD pathogenesis Targeted AD therapies that inhibit IL-13 A detailed patient case to highlig…

1
Innovations in NCFBE: Latest Advances and Personalization of Treatment 15:39

6M ago15:39

15:39

In this podcast, Anne E. O’Donnell, MD, discusses the latest advances and treatment strategies for patients with non–cystic fibrosis bronchiectasis (NCFBE), including: Airway clearance as a foundation of NCFBE management Strategies to address inflammation and exacerbations Emerging therapies in clinical development How to individualize treatment to…

1
Heart Failure and MRAs: Diving Deep Into the Pivotal FINEARTS-HF Trial 22:14

6M ago22:14

22:14

In this podcast, Ty J. Gluckman, MD, MHA, discusses the pivotal phase III FINEARTS-HF trial and how the treatment landscape is evolving for patients with heart failure (HF) with mildly reduced or preserved ejection fraction, including: The emerging role of mineralocorticoid receptor antagonists in HF care Finerenone’s efficacy in reducing composite…